On June 23, Insilico Medicine rose 5.95% in regular trading, trading at HKD 42.4/share, with turnover of HKD 85.69 million, extending the prior session's strong momentum.

On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals targeting AI-driven innovative drug candidates for CNS neuroimmunology disorders. Under the agreement, Insilico Medicine is eligible for up to USD 18 million in upfront and near-term milestone payments, with the potential total deal value exceeding USD 2.5 billion, encompassing development, regulatory, and commercialization milestones as well as single-digit royalties on net sales. This marks the latest in a series of partnerships secured this year — including deals with Servier, Hengtai Bio, Qilu Pharma, Eli Lilly, and others — bringing total new signed deal value to nearly USD 6.5 billion. The collaboration further validates the company's Pharma.AI platform capabilities, with multiple brokerages initiating coverage with Buy ratings and UBS setting a target price of HKD 77.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)